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Asthma is a disease of chronic airway inflammation in which T
helper (Th) 2 cells play a critical role. The molecular mechanisms
controlling Th2 differentiation and function are of paramount
importance in biology and immunology. PKC has been implicated
in the regulation of apoptosis and NF-B, as well as in the control
of T-dependent responses, although no defects were detected in
naı¨ve T cells from PKC/ mice. Here, we report that PKC is critical
for IL-4 signaling and Th2 differentiation. Thus, PKC levels are
increased during Th2 differentiation, but not Th1 differentiation,
of CD4 T cells, and the loss of PKC impairs the secretion of Th2
cytokines in vitro and in vivo, as well as the nuclear translocation
and tyrosine phosphorylation of Stat6 and Jak1 activation, essen-
tial downstream targets of IL-4 signaling. Moreover, PKC/ mice
display dramatic inhibition of ovalbumin-induced allergic airway
disease, strongly suggesting that PKC can be a therapeutic target
in asthma.
apoptosis  asthma  NF-B
Asthma is a chronic lung inflammatory disease with increasedprevalence in developed countries. The pathology of
asthma is associated with aberrant activation of CD4 lympho-
cytes differentiated along the T helper (Th) 2 lineage (1). Naı¨ve
CD4 Th cells can differentiate in response to antigen stimula-
tion into two distinct subsets of effector cells, Th1 and Th2, which
display distinct cytokine profiles and immune regulatory func-
tions (2). Th1 cells mainly produce IFN- and IL-2 and are
essential for cell-mediated immune responses against intracel-
lular pathogens. Th2 cells produce a different set of cytokines,
including IL-4, IL-5, IL-10, and IL-13, and are important in the
control of humoral immunity and allergy (3). The signaling
pathways controlling Th2 differentiation and function have been
the focus of intense research because they could help to identify
therapeutic targets for asthma and other allergic pathologies.
IL-4 is important for induction and maintenance of differenti-
ated Th2 cells and for B cell Ig isotype switching to IgE in mice
(4). IL-4 and IL-13 share interactions with the IL-4R chain and
activate the transcription factor Stat6 through a Jak1Jak3
signaling pathway (3, 5).
The role of the different PKC isoforms in lymphocyte acti-
vation and differentiation is a matter of great interest. The recent
generation of mutant mice in which different PKC isotypes have
been genetically inactivated reveals the selective involvement of
each PKC isoform in cell-specific aspects of the immune re-
sponse (6). The characterization of knockout mice for the
diacylglycerol-insensitive atypical PKC isoform reveals an im-
portant role of this kinase in the immune system (7). Thus,
PKC/ adult mice are unable to mount an optimal immune
response (8), suggesting alterations in lymphocyte function.
Although the humoral response to a T-independent antigen was
reduced in the PKC/ mice, the major defects were found in
mice challenged with a T-dependent antigen, specifically, in the
levels of IgG1, IgG2a, and IgG2b (8). Also, basal IgE levels were
dramatically reduced in PKC/ mice compared with WT
controls (8), indicating that some kind of T cell alteration,
possibly in the Th2 lineage, might be produced by the loss of
PKC. Surprisingly, although the ability of B cells to proliferate
in response to B cell receptor challenge was reproducibly im-
paired in the PKC-deficient mice, no major alterations were
observed in the proliferation of naı¨ve T cells (8). However, the
potential role of PKC in Th2 function and asthma had not been
addressed previously.
Materials and Methods
Mice.PKC/ andWTmice (SV129J background) are described
in ref. 7. Mice aged between 6 and 8 weeks were used for the in
vitro experiments. Age- and sex-matched 10- to 12-week-oldmice
were used for the in vivo asthma model.
Antibodies and Reagents. Antibodies to murine CD3 (145-2C11)
and CD28 (37.51) and biotinylated CD8 (53-6.7), CD11b
(Mac-1), CD16 (2.4G2), CD19 (1D3), CD24 (M169), CD62L
(MEL-14), CD117 (2B8), B220 (RA3-6B2), and CD4-FITC
(L3T4) as well as IL-4-phycoerythrin (PE) and CD25-PE (PC61)
were from Pharmingen. Antibodies to Stat6 (S-20), phospho-
extracellular signal-regulated kinase (ERK) (E-4), ERK1 (K-
23), phospholipase C- (Y783), GATA3 (HG3–31), c-Maf (M-
153), actin (I-19), T-bet (4B10), proliferating cell nuclear antigen
(FL-261), and nuclear factor of activated T cells (NFAT) c1
(7A6) were from Santa Cruz Biotechnology. Stat5, Jak1, phos-
pho-Stat6 (Tyr-641), phospho-Stat5 (Y694), and phospho-Jak1
(Tyr-1022 and Tyr-1023) antibodies were from Cell Signaling
Technology (Beverly, MA). Recombinant murine IL-2, IL-12,
and IL-4 as well as anti-IFN-, anti-IL-5, anti-IL-4R, and
anti-IL-4 antibodies were from R & D Systems. IFN-, IL-4,
IL-5, and IL-10 ELISA kits were from Pharmingen, and the
IL-13 ELISA kit was from R & D Systems. Specific polyclonal
anti-PKC antibody was generated against the sequence encom-
passing amino acids 185–244 of PKC.
CD4 T Cell Isolation and Differentiation. To obtain naı¨ve CD4 T
cells, single cell suspensions were prepared from spleens and
mesenteric lymph nodes of the indicated mice and were incu-
bated with biotinylated antibodies directed at CD8, CD16,
CD19, CD24, CD117, major histocompatibility complex class II
(I-Ab), and CD11b followed by incubation with anti-biotin-
conjugated microbeads. Naı¨ve CD4 T cells were negatively
selected in an autoMACS separator (Miltenyi Biotec, Auburn,
CA) according to the manufacturer’s instructions. Purified
CD4 T cells were labeled with antibodies specific for CD4,
CD25, CD62L, and B220 and analyzed by flow cytometry to
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confirm purity and the naı¨ve status (Fig. 6, which is published as
supporting information on the PNAS web site). Naı¨ve CD4 T
cells (106 cells per ml) were differentiated in the presence of
irradiated antigen-presenting cells (106 cells per ml), immobi-
lized anti-CD3 (1 gml), and IL-2 (10 ngml). For Th0 cultures,
anti IL-4 (4 gml) and anti-IFN- (4 gml) were added. For
Th1 differentiation, IL-12 (3.5 ngml) and anti-IL-4 (4 gml)
were added to the culture, whereas IL-4 (4 ngml) and anti-
IFN- (4 gml) were added for Th2 differentiation. After 4
days, the cells were extensively washed, counted, and restimu-
lated as described. No differences in viability were observed in
WT and knockout naı¨ve Th0, Th1, or Th2 cells.
FACS Analysis and Intracellular Staining. GATA3 protein levels
were assessed by intracellular staining in cells fixed overnight
with 70% ethanol at 20°C and stained with anti-GATA3 or
control mouse IgG1 followed by FITC-anti-mouse IgG1. To
determine intracellular IL-4 levels, brefeldin A (BD GolgiPlug,
BD Biosciences) was added 4 h before harvest to Th2 polarized
WT and PKC/ cells that had been restimulated for 48 h with
anti-CD3 in the absence or presence of anti-CD28. Afterward,
cells were fixed and permeabilized by using the BD Cytofix
Cytoperm kit (BD Biosciences) and stained with anti-IL-4-
phycoerythrin. Analysis was performed in a FACSCalibur cell
sorter (BD Biosciences) with CELLQUESTPRO software.
PKC Kinase Assay. Cell extracts prepared in lysis buffer (50 mM
TrisHCl, pH 7.5150 mM NaCl1 mM EGTA2 mM EDTA1%
Triton X-100) were immunoprecipitated with the specific anti-
PKC antibody that does not crossreact with PKC for 2 h at 4°C.
Immunoprecipitates were captured with protein A and washed
extensively in lysis buffer with 0.5MNaCl. The enzymatic assay was
carried out in the immunoprecipitates in assay buffer [35 mM
TrisHCl, pH 7.510 mM MgCl2100 M CaCl20.5 mM EGTA
100 M ATP5 Ci (1 Ci  37 GBq) of [32P]ATP] with 4 g of
myelin basic protein as substrate for 1 h at 30°C.
Cytokine Assays.Naı¨ve CD4T cells were stimulated for 72 h with
anti-CD3 (10 gml) plus anti-CD28 (5 gml), and Th2-
differentiated cells were restimulated for 24 h with anti-CD3 (10
gml), after which, supernatants were collected and cytokine
concentrations were measured by ELISA using commercially
available kits. ELISA was also used to determine the levels of
Th2 cytokines in bronchoalveolar lavage (BAL) fluids.
Immunofluorescent Analysis. Th2 cells (2  105) were applied to
glass slides by cytocentrifugation. Cells were fixed, permeabil-
ized with 0.1% Triton X-100, and incubated with the different
antibodies for 1 h at 37°C and the tetramethylf luorescein tyra-
mide TSA-Direct amplification system (NEN). For the nuclear
staining, cells were incubated with TO-PRO. Glass coverslips
were mounted on Mowiol and examined with an MRC 1024
confocal system (Bio-Rad) mounted on an Axiovert 135 micro-
scope (Zeiss).
Ovalbumin (OVA)-Induced Allergic Airway Disease. PKC/ and
WTmice (10–12 weeks old) were immunized as described in ref.
9. Briefly, on day 0, 15 g of OVA (Sigma) in 200 l of alum
(Pierce) were injected i.p. into sensitized mice. On day 5, the
animals received another i.p. injection of 15 g of OVA in 200
g of alum and, on day 12, mice were challenged with aerosolized
0.5% OVA in PBS (two challenges of 60 min each that were 4 h
apart). Control animals were aerosolized with PBS. On day 14,
40 h after the second OVA challenge, mice were killed for
analysis. For histological analysis, lungs from PBS- or OVA-
treated mice were inflated through the trachea with 50% Jung
tissue-freezing medium (Leica, Vienna) in PBS. The right caudal
lobe was trimmed, embedded, frozen, and stored at 80°C. For
the adoptive transfer experiments, WT and PKC/ mice were
i.p. injected with 100 g of OVA in 2 mg of alum, and, 5 days
later, spleens and mesenteric lymph nodes were removed for
CD4 T cell isolation and were cultured for Th2 differentiation
for 4 days with irradiated antigen-presenting cells, OVA (50
gml), IL-2 (10 ngml), IL-4 (10 ngml), and anti-IFN- (10
gml). Afterward, Th2-like cells were collected, washed, and
i.v. injected into WT and PKC/ recipient mice, which, 24 h
later, were exposed to inhaled 1% OVA in PBS for a total of 7
days (4 consecutive days exposed, 2 days rested, and 3 consec-
utive days exposed) for 20 min daily. Mice were killed 24 h after
the final exposure to antigen, and histological analysis of lungs
was performed. The appropriate institutional animal use and
care committees approved all animal experiments.
Statistical Analysis. Statistical analyses were performed by using
Student’s t test. P  0.05 was considered to be significant.
Results
Impaired Th2 Differentiation in PKC/Mice. To determine whether
PKC may play a role in lineage commitment of CD4 T helper
cells, we initially differentiated CD4 T cells, either WT or
PKC/, in vitro under Th1 or Th2 polarizing conditions, after
which, cells were stimulated with anti-CD3 antibody for 48 h, and
the secretion of IFN- and IL-4 was determined in the Th1 and Th2
cultures, respectively. Results in Fig. 1a show that whereas IFN-
secretion is not affected, IL-4 is significantly reduced in PKC/
cells (Fig. 1a). The synthesis of three other Th2 cytokines, IL-5,
IL-10, and IL-13, was also dramatically inhibited in PKC/ Th2
cells (Fig. 1a). When the levels of intracellular IL-4 were deter-
mined in the presence of brefeldin A by FACS analysis, it was clear
that WT Th2 cells produce significantly more IL-4 than do
PKC/ Th2 cells (Fig. 1b), consistent with the ELISA data in Fig.
1a. Together, these results suggest that PKC plays a nonredundant
role in Th2-polarized CD4 T cells.
GATA3 expression is a widely established hallmark of the Th2
polarization process (10). Therefore, we initially analyzed by using
flow cytometry the levels of this transcription factor inCD4T cells
incubated under Th0, Th1, and Th2 polarizing conditions. Inter-
estingly, the loss of PKC significantly reduces GATA3 expression
in Th2 cells (Fig. 2a), strongly suggesting that PKC plays an
important role during Th2 differentiation. Consistent with this
notion, the levels of GATA3, as well as the levels of Stat6, c-Maf,
RelA, and NFATc1, were dramatically reduced in PKC-deficient
Th2 cells as determined by immunoblotting (Fig. 2b). Interestingly,
when Th2-polarized T cells were rechallenged with anti-CD3 plus
anti-CD28, the nuclear levels of all of the transcription factors
tested were likewise inhibited in the PKC/ cells (Fig. 2c).
Therefore, it seems that PKC is required for the Th2 differenti-
ation process to properly occur and for Th2-polarized cells to
respond to an anti-CD3 rechallenge.
Signaling Cascades Inhibited in PKC/ T Cells Induced to Differen-
tiate Along the Th2 Pathway.BecausePKC appears to be important
for Th2 polarization, we next sought to determine whether this
kinase is induced during this important differentiation process.
First, we generated a polyclonal antibody that selectively recognizes
PKC and that does not crossreact with PKC. The result in Fig.
3a shows the specificity of this antibody in immunoblot analysis of
lung extracts, a tissue particularly rich in PKC (7), from WT and
PKC/ mice. Immunoblotting with an anti-PKC-specific an-
tibody of the same extracts reveals that the levels of this aPKC
isoform were not affected by the loss of PKC (Fig. 3a). Therefore,
we next prepared extracts from CD4 T cells incubated under Th0,
Th1, or Th2 conditions, and the expression of PKC was deter-
mined by immunoblotting with our selective antibody. The data in
Fig. 3b demonstrate that PKC levels are increased under Th2
polarizing conditions, but not under Th1 polarizing conditions.









Immunoblotting with anti-GATA3 and anti-T-bet demonstrated
that cells were properly polarized to the Th2 and Th1 lineages,
respectively (Fig. 3b). To determine whether this induced PKC is
enzymatically active, we immunoprecipitated this kinase from
polarized CD4 T cell extracts, and the enzymatic activity was
determined in a standard kinase assay. The data in Fig. 3b show that
the activity of PKC is pronouncedly induced in Th2 cells.
Based on these observations and the impairment of Th2 differ-
entiation and function of PKC/ T cells, we considered it
important to determine whether PKC is activated in Th2 cells
upon T cell receptor (TCR) activation. Thus, CD4 T cells polar-
ized under Th2 conditions were incubated with anti-CD3, and,
afterward, PKC enzymatic activity was determined as above. The
incubation with anti-CD3 triggers a dramatic increase in PKC
activity (Fig. 3c) without appreciable changes in the levels of the
enzyme (Fig. 3c). Collectively, these results indicate that PKC is
activated when Th2-polarized CD4 T cells are rechallenged with
anti-CD3. Th differentiation is modulated by signals emanating
from the TCR and the cytokines generated during this polarization
process, particularly IL-4, which is present in the culture medium of
CD4 T cells induced to differentiate to the Th2 lineage. Impor-
tantly, IL-4 is synthesized by Th2 cells when rechallenged with an
anti-CD3 antibody in the absence of any exogenous cytokine, which
exerts a positive feedback activation loop (11). To determine
whether PKC activation in CD3-triggered CD4 T cells polarized
under Th2 conditions is a direct effect of TCR signaling or whether
it is mediated by the secreted IL-4, WT CD4 Th2 cells activated
with anti-CD3were incubated in the presence of either neutralizing
anti-IL-4 or anti-IL-5 antibodies, after which, PKC activity was
determined as above. According to the results of Fig. 3c, PKC
activation by anti-CD3 is dramatically inhibited by the presence of
anti-IL-4 but not by the presence of anti-IL-5 (Fig. 3c). These results
indicate that IL-4 is responsible for the activation of PKC in
CD3-restimulatedTh2 cells and that PKC could be part of the IL-4
Fig. 1. Role of PKC in Th2 differentiation and cytokine synthesis. (a)
Secretion of IFN- in Th1 cells or IL-5, IL-4, IL-13, and IL-10 in Th2 cells inWT or
PKC/ (KO)mice stimulatedwith anti-CD3was determined by ELISA. (b) IL-4
intracellular staining of Th2 cells inWT or PKC/ (KO) mice either untreated
or treated with anti-CD3 alone or in combination with anti-CD28. Inset
numbers represent thepercentageof IL-4-positive cells. The results inaare the
mean  SD of three independent experiments with incubations in triplicate.
The results inb are representative of another twoexperiments. ***, P 0.001.
Fig. 2. Th2 transcription factors in PKC/ cells. (a) Intracellular staining of
GATA3 in Th0, Th1, and Th2 cells in WT or PKC/ (KO) mice. The solid line
represents GATA3 staining; the dashed line corresponds to the mouse IgG1
isotype control. Inset numbers represent the percentage of GATA3-positive
cells. (b and c) Western blot analysis of nuclear levels of GATA3, Stat6, RelA,
c-Maf, and NFATc1 in cell cultures as above (b) or in Th2 cells stimulated with
anti-CD3plus anti-CD28 (c). Anti-proliferating cell nuclear antigenwasusedas
a loading control in b and c. The results are representative of three indepen-
dent experiments.
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signaling machinery but that it is not a direct step in the TCR signal
transduction cascade. To address this point, naı¨ve CD4 T cells
were incubated with IL-4 for different times, and PKC enzymatic
activity was determined as above. Interestingly, the addition of IL-4
provokes a reproducible and robust activation of PKC in these cells
(Fig. 3d), demonstrating that PKC constitutes a potentially im-
portant step in IL-4 signaling. If this model is correct, that would
imply that the activation of signaling cascades of the TCR should
not be impaired in the PKC/ naı¨ve CD4 T cells but that the
stimulation of the IL-4 pathway should be inhibited. To address this
point, we incubated naı¨ve WT and PKC/ CD4 T cells with or
without IL-4, after which, tyrosine phosphorylation of Stat6 and
Jak1 was determined by immunoblotting with phospho-site-specific
antibodies. Results in Fig. 3e Left demonstrate that the loss of PKC
dramatically impairs the activation of Stat6 and Jak1 in naı¨ve CD4
T cells. However, the loss of PKC does not affect the activation of
ERK or NFATc1 (Fig. 3f) or that of NF-B (Fig. 3g) or IB kinase
activity (Fig. 3h) in these cells when stimulated with anti-CD3 plus
anti-CD28. The secretion of IL-4 and IL-5 in naı¨ve CD4 T cells
activated with anti-CD3 is normal in the PKC/ cells (Fig. 3i),
reinforcing the notion that PKC is not a direct target of TCR
signaling. Likewise, the loss of PKC did not affect IL-2-induced
Stat5 activation in this system (Fig. 3e Right). Taken together, these
results suggest that the defect inTh2-polarized cells is accounted for
by the important role played by PKC in IL-4 signaling but not in
TCR downstream events. This model is consistent with our previ-
ously published results that demonstrated the lack of defects in the
proliferation of naı¨ve T cells from PKC/ mice, a phenomenon
that is clearly dependent on IL-2 production and signaling (8). In
contrast, because the common -chain receptor is essential for IL-2
and IL-4 function, the fact that IL-2 signaling is intact in the
PKC/mice (Fig. 3e Right) indicates that the defects observed in
the IL-4 pathway cannot be explained by potential alterations in the
levels of this receptor subunit. In addition, the data in Fig. 7, which
is published as supporting information on the PNAS web site,
demonstrate that the levels of the -chain of the IL-4 receptor are
intact in naı¨ve and Th2-polarized T cells as demonstrated by FACS
analysis to detect surface expression of the receptor (Fig. 1a) and
immunoblotting (Fig. 1b). Interestingly, the nuclear translocation of
activated Stat6 is dramatically inhibited in the PKC/ Th2 cells
(Fig. 4a), and the exogenous addition of IL-4 does not bypass this
blockade (Fig. 4b). These results are consistent with the notion that
PKC is required for the efficient activation of Jak1 and the
subsequent phosphorylation and nuclear translocation of Stat6.
Loss of PKC Inhibits Allergic Airway Disease. It is well established
that the Th2 immune response is responsible of the development of
allergic airway inflammation (12–15). Because the loss of PKC
results in impaired Th2 activation, we reasoned that PKC/mice
would display reduced inflammatory response in a model of
Fig. 3. Biochemical signaling pathways in PKC/ cells. (a) Western blot analysis of PKC and PKC in lung fromWT and PKC/ (KO) mice. (b) Extracts from
CD4 T cells incubatedunder Th0, Th1, or Th2polarizing conditionswere analyzedby immunoblotting for PKC, GATA3, and T-bet expression andby PKC kinase
activity (KA). (c) WT Th2-polarized T cells were incubated with or without anti-CD3 in the presence or absence of neutralizing anti-IL-4 or anti-IL-5 antibodies,
and PKC kinase activity (KA) and PKC levels were determined. (d) PKC kinase activity (KA) and PKC levels were measured in Th2-polarized cells stimulated
with IL-4 for different times. (e) Naı¨ve CD4 T cells were stimulated or not stimulated with IL-4 or IL-2 for 10 min; afterward, phospho-Stat6, phospho-Jak1, and
phospho-Stat5 levels, aswell as levels of Stat6, Jak1, and Stat5,were determined by immunoblotting. ( f)Western blot analysis of phospho-ERK, ERK, andNFATc1
in naı¨ve CD4 T cells stimulated with anti-CD3 plus anti-CD28. (g) NF-B activation was analyzed by EMSA in nuclear extracts prepared from naı¨ve CD4 T cells
stimulated with anti-CD3 plus anti-CD28. (h) IB kinase activity was determined in the above extracts. The results are representative of three independent
experiments. (i) Cytokine production of IL-4 and IL-5 analyzed by ELISA in naı¨ve CD4 T cells, eitherWT or PKC/ (KO), stimulatedwith anti-CD3 plus anti-CD28.
The results are the mean  SD of three independent experiments with incubations in triplicate.









OVA-induced allergic airway disease that predominantly generates
a Th2 response. Therefore, mice that are either WT or PKC/
were sensitized toOVA and then challenged twice with aerosolized
antigen or PBS on the same day. Forty-eight hours after the aerosol
challenge, mice were killed, the lungs were examined histologically
by hematoxylineosin (H&E) staining for eosinophilic infiltration,
and BAL was performed to determine inflammatory cell recruit-
ment. There was a robust increase in total BAL cell numbers inWT
mice that were OVA sensitized and challenged with aerosolized
antigen compared with PBS-challenged mice (Fig. 5a Left), due
especially to eosinophils (Fig. 5a Right). However, this increase was
dramatically reduced in the PKC/mice (Fig. 5a), indicating that
the impairment in the Th2 response observed in these mutant mice
inhibits airway inflammation. Consistent with this notion, H&E
histological analysis of lung sections from this experiment shows
that whereas the challenged WT mice display a prominent inflam-
matory response with massive perivascular and peribronchial infil-
tration with abundant eosinophils, PKC/ mice display a much
more attenuated response (Fig. 5b). CD11b staining confirms a
dramatic reduction in granulocyte infiltration in the OVA-
challenged PKC/ mice (Fig. 5c). The production of mucus in
asthmatic patients is severely debilitating and may lead to death.
Periodic acid Schiff’s base staining of lung sections consistently
showed mucus production in the airway epithelium and alveoli of
WT mice. In contrast, and concurring with the milder allergic
response to the OVA challenge observed in the PKC/ mice,
mucus production was not observed in lung sections from these
animals (data not shown). In addition, BAL IL-4, IL-5, IL-13, and
eotaxin (Fig. 5d) supernatant levels, which were dramatically in-
creased in OVA-challenged WT mice, were severely reduced in
similarly treated PKC/ mice.
Adoptive Transfer Experiments Support a Critical Role of PKC in Th2
Function. The results from the asthma model experiments are
consistent with a critical role of PKC in Th2 function. However, it
would be of great interest to determine whether this phenotype is
mostly due to defects in Th2 cells or whether the loss of PKC in
Fig. 4. PKC is required for Stat6 nuclear translocation. Th2 polarizedWT or
PKC/ (KO) cells were restimulated or left unstimulated with anti-CD3 or
anti-CD3 plus anti-CD28 in the absence (a) or presence (b) of IL-4, and nuclear
translocation of Stat6 was determined by confocal analysis. Stat6 (green) or
TO-PRO nuclear (blue) staining was visualized. The results are representative
of three independent experiments.
Fig. 5. Role of PKC in OVA-induced allergic airway disease. (a–d) OVA-
induced allergic airway inflammation is impaired in PKC/ mice. Total cell
numbers and eosinophils in BAL fluids were determined (a). Lung sections
were prepared and stained with H&E (b) or with anti-CD11b (c). Levels of IL-4,
IL-5, IL-13, and eotaxin in the BAL fluids were measured by ELISA (d). (e)
Adoptively transferred Th2 WT into PKC/ (KO) cells can generate airway
inflammation. Th2 WT and PKC/ (KO) cells were generated by using mice
sensitizedwithOVAandalum.Th2cellswere collectedand injected intoeither
WT or PKC/ (KO) recipient mice. The mice were exposed to aerosolized
OVA, and lungs were prepared for histology and stained with H&E. Data
shown are representative of two experiments that each time involved six WT
and six PKC/ (KO)mice.aanddare themean SD;n6 for eachgenotype.
**, P  0.01; ***, P  0.001.
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the lung resident cells might contribute to the inhibition in allergic
airway inflammation observed in the PKC mutant mice. To
address this question, we transferred in vitro-generated WT and
PKC/ Th2 cells into PKC/ mice and determined the sensi-
tivity of these mice to the asthma model. Following a previously
established method (16), we induced Th2 cells by i.p. injections of
WT and PKC/ mice with OVA, and, after 5 days of immuni-
zation, CD4 T cells from spleens and lymph nodes were isolated
and subsequently cultured with antigen-presenting cells, OVA, and
IL-4 for 4 days. Afterward, Th2-polarized cells were i.v. injected in
equal numbers into WT and PKC/mice, whereas some control
WT and PKC/ mice did not receive cells. Mice were then
challenged with inhaled OVA as described in Materials and Meth-
ods. Twenty-four hours after the final challenge, mice were killed,
and lung inflammationwas analyzed histologically byH&E staining
as above. Importantly, H&E histological analysis of lung sections
from this experiment shows that whereas the challenged PKC/
mice that have been injected with PKC/ Th2 cells showed little
or no inflammation, the mutant mice injected with WT Th2 cells
displayed aprominent inflammatory responsewithmassive perivas-
cular and peribronchial infiltration (Fig. 5e). In contrast, the WT
control mice that were not challenged showed no inflammation at
all (Fig. 5e). Also, the injection of PKC/ Th2 cells intoWTmice
did not produce significant inflammation (Fig. 5e). These results
suggest that the loss of PKC in the lung resident cells does not
contribute in a significant manner to the OVA-induced airway
inflammatory response and demonstrate the critical role of PKC
in Th2 function in vivo.
Discussion
The understanding of the signaling cascades that regulate asthma,
and Th2 polarization in particular, is an important issue in immu-
nology. Because Th2 cells are critical players in the orchestration of
the networks activated during allergic airway inflammation, these
signaling pathways are a rich source of therapeutic targets in asthma
and possibly other allergic diseases. The fact that PKC is a critical
modulator of the Th2 response strongly suggests that it is a
potentially relevant target for these pathological alterations of the
immune system. Our data indicate that the loss of PKC leads to a
clear impairment in the secretion of Th2 cytokines in ex vivo and in
vivo experiments due to the inability of the PKC/ CD4 T cells
to differentiate adequately along the Th2 lineage. Thus, the loss of
PKC results in the generation of Th2 cells in ex vivo cultures that
poorly activate GATA3, c-Maf, Stat6, and NFATc1 during the Th2
differentiation program. Also, RelA activation is impaired in the
PKC/ cells. Although PKC has been shown to be involved in
NF-B nuclear translocation and IB kinase activation in lung (7)
and liver (17), we think that the defect observed in RelA activation,
and in the other transcription factors, in Th2-polarized cells is
secondary to an impaired differentiation program in the mutant
cells due to the essential role played by PKC in IL-4 signaling. In
this regard, Th2 differentiation in vitro is triggered by TCR activa-
tion and the IL-4 present in the culture medium. Notably, the
activation of PKC in anti-CD3-rechallenged Th2 cells requires the
autocrinely secreted IL-4, suggesting that PKC is not a direct
downstream target of the TCR pathway but is a critical mediator of
IL-4 signal transduction. Consistent with this model, IL-4 is suffi-
cient to activate PKC in naı¨ve T cells, and the loss of this kinase
impairs Jak1Stat6 activation by IL-4 in these cells, whereas it is
dispensable for the activation of TCRproximal signals such as ERK
and NF-B activation. Therefore, the results presented here estab-
lish PKC as a critical player in the Th2 differentiation programs
downstream the IL-4 receptor and independently from TCR-
activated signals. The data are consistent with our previously
published results that demonstrated that PKC is not involved in
TCR-driven activation of naı¨ve T cell proliferation and IL-2 pro-
duction (8). Interestingly, the loss of PKC leads to impaired Stat6
tyrosine phosphorylation and nuclear translocation due to the fact
that PKC is required for the proper stimulation of Jak1. Our
previous results indicated that PKC interacts with and phosphor-
ylates Jak1 in vitro and in IL-4 activated cells (17), which offers a
mechanistic explanation to the Th2 inflammatory phenotype of the
PKC mutant mice reported here.
Particularly relevant from the point of view of lung inflammatory
pathologies are our results from the OVA-induced allergic airway
disease model. These data validate PKC in asthma, because the
mutant mice show a dramatically reduced response to OVA-
induced airway inflammation. This response is the consequence of
a complex set of cellular interactions involving the recruited Th2
lymphocytes and lung resident cells (1, 11). Of note, adoptive
transfer experiments reported in this study demonstrate that the
loss of PKC in lung resident cells does not contribute significantly
to the impairment of the inflammatory response in this system,
whereas the loss of PKC in Th2 cells is of great importance. These
data reinforce the notion that PKC is required for Th2 function
due to its critical role in IL-4 signaling. Our results also explain
previous observations that PKC/mice have defects in mounting
an optimal adaptive immune response to a T-dependent antigen
without a defect in naı¨ve T cell activation (8). Thus, our system is
different from the PKC	/mice. In contrast to the PKC/mice,
which have a defect in Th2 cells but not in naı¨ve T cell proliferation
(8), in the case of the PKC	/ mice, the alterations were not
restricted to the Th2 differentiation program (18–20); defects were
also found inNF-Bactivation andproliferation of naı¨veT cells (21,
22), suggesting that the role of PKC is more constrained to the Th2
polarization mechanism and that the role of PKC	 has a broader
impact in T cell function.
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